Boston Scientific Corporation vs iShares Core MSCI EAFE ETF — how do they compare? Boston Scientific Corporation trades at $42.51 (market cap $66.37B), while iShares Core MSCI EAFE ETF trades at $97.33. The key difference: iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | IEFA | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $108.14 | $98.56 |
52-Week Low | $42.63 | $81.70 |
Enterprise Value | $75.94B | — |
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
IEFA trades at $96.15, down 1.1% on the day, with technical indicators showing a neutral to bearish short-term bias. The ETF provides exposure to developed international markets outside the US and Canada, offering diversification benefits amid S&P 500 concentration concerns. Recent news highlights IEFA's competitive 3.30% dividend yield and low 0.07% expense ratio compared to peers like VXUS and EEM.
The outlook remains balanced with potential upside from Fed rate cuts and international diversification benefits, offset by currency risks and developed market monetary policy tightening. IEFA's low-cost structure and dividend yield provide defensive characteristics, though performance depends heavily on international economic conditions and currency movements.
Trailing returns across standard periods
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →